probucol has been researched along with Hyperplasia in 10 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Hyperplasia: An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Thus, treatment with probucol, a potent antioxidant agent that has been shown to reduce restenosis after balloon angioplasty, may be an effective strategy to prevent intimal hyperplasia after stenting." | 9.12 | Role of probucol in inhibiting intimal hyperplasia after coronary stent implantation: a randomized study. ( Abizaid, AC; Belló-Klein, A; Brito, FS; Caixeta, A; Clausell, N; da Silva, LF; Mazzotti, NG; Nunes, GL; Theodoro, MP, 2006) |
| " Thus, treatment with probucol, a potent antioxidant agent that has been shown to reduce restenosis after balloon angioplasty, may be an effective strategy to prevent intimal hyperplasia after stenting." | 5.12 | Role of probucol in inhibiting intimal hyperplasia after coronary stent implantation: a randomized study. ( Abizaid, AC; Belló-Klein, A; Brito, FS; Caixeta, A; Clausell, N; da Silva, LF; Mazzotti, NG; Nunes, GL; Theodoro, MP, 2006) |
| "Intimal hyperplasia is a persistent problem after implantation of prosthetic grafts." | 1.29 | Probucol reduces the cellularity of aortic intimal thickening at anastomotic regions adjacent to prosthetic grafts in cholesterol-fed rabbits. ( Baumann, DS; Daugherty, A; Doblas, M; Schonfeld, G; Sicard, GA, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, M | 1 |
| Xu, B | 1 |
| Kandzari, DE | 1 |
| Wu, Y | 1 |
| Yan, H | 1 |
| Chen, J | 1 |
| Qian, J | 1 |
| Qiao, S | 1 |
| Yang, Y | 1 |
| Gao, RL | 1 |
| Wu, BJ | 3 |
| Midwinter, RG | 1 |
| Cassano, C | 1 |
| Beck, K | 2 |
| Wang, Y | 2 |
| Changsiri, D | 1 |
| Gamble, JR | 1 |
| Stocker, R | 3 |
| Ni, J | 1 |
| Santiago, FS | 1 |
| Malabanan, KP | 1 |
| Li, C | 1 |
| Khachigian, LM | 1 |
| Wakeyama, T | 1 |
| Ogawa, H | 1 |
| Iida, H | 1 |
| Takaki, A | 1 |
| Iwami, T | 1 |
| Mochizuki, M | 1 |
| Tanaka, T | 1 |
| Tanous, D | 1 |
| Bräsen, JH | 1 |
| Choy, K | 1 |
| Kathir, K | 1 |
| Lau, A | 1 |
| Celermajer, DS | 1 |
| Nunes, GL | 1 |
| Abizaid, AC | 1 |
| Theodoro, MP | 1 |
| Brito, FS | 1 |
| Caixeta, A | 1 |
| da Silva, LF | 1 |
| Mazzotti, NG | 1 |
| Belló-Klein, A | 1 |
| Clausell, N | 1 |
| Yang, YB | 1 |
| Yang, YX | 1 |
| Su, B | 1 |
| Tang, YL | 1 |
| Zhu, BY | 1 |
| Hu, ZW | 1 |
| Li, GY | 1 |
| Li, YJ | 1 |
| Liao, DF | 1 |
| Wu, TC | 1 |
| Chen, YH | 1 |
| Leu, HB | 1 |
| Chen, YL | 1 |
| Lin, FY | 1 |
| Lin, SJ | 1 |
| Chen, JW | 1 |
| Baumann, DS | 1 |
| Doblas, M | 1 |
| Schonfeld, G | 1 |
| Sicard, GA | 1 |
| Daugherty, A | 1 |
| Ishizaka, N | 1 |
| Kurokawa, K | 1 |
| Taguchi, J | 1 |
| Miki, K | 1 |
| Ohno, M | 1 |
3 trials available for probucol and Hyperplasia
| Article | Year |
|---|---|
First report of a novel polymer-free dual-drug eluting stent in de novo coronary artery disease: results of the first in human BICARE trial.
Topics: Cardiovascular Agents; China; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Drug Com | 2014 |
Effects of candesartan and probucol on restenosis after coronary stenting: results of insight of stent intimal hyperplasia inhibition by new angiotensin II receptor antagonist (ISHIN) trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticholesteremic Agents; Benzimidazoles; Biphenyl Co | 2003 |
Role of probucol in inhibiting intimal hyperplasia after coronary stent implantation: a randomized study.
Topics: Aged; Antioxidants; Blood Vessel Prosthesis Implantation; Coronary Restenosis; Female; Humans; Hyper | 2006 |
7 other studies available for probucol and Hyperplasia
| Article | Year |
|---|---|
Heme oxygenase-1 increases endothelial progenitor cells.
Topics: Animals; Antigens, Ly; Carbon Monoxide; Cells, Cultured; Endothelial Cells; Enzyme Induction; Hemato | 2009 |
Interplay between heme oxygenase-1 and the multifunctional transcription factor yin yang 1 in the inhibition of intimal hyperplasia.
Topics: Animals; Carotid Arteries; Cell Proliferation; Cells, Cultured; Endothelial Cells; Endothelium, Vasc | 2010 |
Probucol inhibits in-stent thrombosis and neointimal hyperplasia by promoting re-endothelialization.
Topics: Animals; Antioxidants; Cell Proliferation; Disease Models, Animal; Follow-Up Studies; Graft Occlusio | 2006 |
Probucol mediates vascular remodeling after percutaneous transluminal angioplasty via down-regulation of the ERK1/2 signaling pathway.
Topics: Angioplasty, Balloon; Animals; Antioxidants; Atherosclerosis; Caveolin 1; Cell Movement; Cell Prolif | 2007 |
Carvedilol, a pharmacological antioxidant, inhibits neointimal matrix metalloproteinase-2 and -9 in experimental atherosclerosis.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antioxidants; Aorta, Abdominal; Atherosclerosis; Carbazoles; C | 2007 |
Probucol reduces the cellularity of aortic intimal thickening at anastomotic regions adjacent to prosthetic grafts in cholesterol-fed rabbits.
Topics: Anastomosis, Surgical; Animals; Antibodies, Monoclonal; Aorta; Blood Vessel Prosthesis; Cholesterol; | 1994 |
Inhibitory effect of a single local probucol administration on neointimal formation in balloon-injured rat carotid artery.
Topics: Administration, Topical; Animals; Anticholesteremic Agents; Carotid Artery Injuries; Carotid Artery, | 1995 |